GILEAD SCIENCES, INC.
10-K
February 24, 2026
Key Highlights
- Robust growth in Oncology & Cell Therapy, with Tecartus, Yescarta, and Trodelvy ...
- Strong financial health with $10.5 billion in operating cash flow and $9.0 billi...
- Continued market leadership in HIV, with Biktarvy sales rising over 5% to $11.8 ...
Read Analysis
🤖 AI Generated